| scholarly article | Q13442814 |
| P50 | author | Martin Tolstrup | Q38325043 |
| Ole Schmeltz Søgaard | Q56984920 | ||
| P2093 | author name string | Peggy Kim | |
| Joseph K Wong | |||
| Steven A Yukl | |||
| Sara Moron-Lopez | |||
| P2860 | cites work | Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial | Q38958099 |
| Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription | Q39173861 | ||
| Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial | Q39361321 | ||
| A5 Peripheral blood cells contribute to HIV-1 viremia induced by romidepsin | Q40068696 | ||
| Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs. | Q41936227 | ||
| What do we measure when we measure cell-associated HIV RNA. | Q47548192 | ||
| HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. | Q52680785 | ||
| Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals | Q57201701 | ||
| Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy | Q28253761 | ||
| Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy | Q28544949 | ||
| Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy | Q29615993 | ||
| Recovery of replication-competent HIV despite prolonged suppression of plasma viremia | Q29615995 | ||
| Romidepsin-induced HIV-1 viremia during effective ART contains identical viral sequences with few deleterious mutations | Q30490742 | ||
| HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat | Q34106191 | ||
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy | Q34290545 | ||
| HIV-1 DNA predicts disease progression and post-treatment virological control | Q34350410 | ||
| Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies | Q34607763 | ||
| The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo | Q35778783 | ||
| Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation | Q36409885 | ||
| Digital detection of endonuclease mediated gene disruption in the HIV provirus. | Q36528328 | ||
| The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption | Q36824388 | ||
| HIV rebounds from latently infected cells, rather than from continuing low-level replication | Q36954950 | ||
| New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. | Q37695001 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 425-431 | |
| P577 | publication date | 2019-03-01 | |
| P1433 | published in | AIDS | Q4651863 |
| P1476 | title | Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals | |
| P478 | volume | 33 |
| Q89836084 | Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial |
| Q64083383 | Cat and Mouse: HIV Transcription in Latency, Immune Evasion and Cure/Remission Strategies |
| Q89875340 | Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART |
| Q93062057 | Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells |
| Q89620873 | Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs |
| Q89685622 | Integrated assessment of viral transcription, antigen presentation, and CD8+ T cell function reveal multiple limitations of class I selective HDACi during HIV-1 latency reversal |
Search more.